TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
University of Virginia researchers report that focused ultrasound, microbubbles and nanoparticles delivered microRNAs into the brains of laboratory and animal models of glioblastoma. The treatment slowed tumor growth and was associated with longer survival in animals, but it remains experimental and has not been tested in human patients.
Researchers at the University of Virginia Comprehensive Cancer Center report that a combination of focused ultrasound, microscopic bubbles and nanoparticles delivered cancer-targeting microRNAs into laboratory and animal models of glioblastoma. In the animal studies, the treatment slowed tumor growth and helped the animals live longer, but the approach remains experimental and has not yet been evaluated in people.
The team, led by Roger Abounader, used small genetic molecules called microRNAs to suppress the activity of multiple genes involved in glioblastoma development and growth. The researchers packaged the microRNAs in specialized nanoparticles, which were intended to carry them into the brain and release them near the tumor.
To help the particles pass through the brain’s normally protective blood-brain barrier, the team combined them with microbubbles and focused ultrasound guided by MRI. The ultrasound was directed at the intended area, and the bubbles helped create a temporary opening in the barrier, providing a short window for the nanoparticles to enter brain tissue.
According to the report, the approach was tested in laboratory experiments and animal models. The findings showed slower tumor growth and longer survival among treated animals. The supplied report does not give figures for the size of the effect, the number of animals studied or the length of follow-up, so the results cannot establish how well the treatment might work in people.
A Different Way to Reach Brain Tumors
The research addresses two challenges in glioblastoma treatment: the difficulty of delivering therapies across the blood-brain barrier and the tumor’s involvement of multiple cancer-related genes. The researchers’ approach pairs a delivery method with microRNAs that can affect more than one gene, rather than relying solely on medicines aimed at individual targets.
If later studies support the early findings, the combination could offer a way to investigate targets that currently lack available drugs. That possibility is a research rationale, not a demonstrated benefit for patients. The present evidence is limited to preclinical work; it does not show that the method is safe, effective or ready for clinical use.
That distinction matters for people facing glioblastoma, an aggressive cancer that is difficult to remove completely because its cells can spread into nearby healthy brain tissue. The UVA report says the disease claims more than 13,000 lives in the United States each year. The new work is an early laboratory-stage development, not a change to current patient care.
Products Worth Considering
Philips Sonicare ProtectiveClean 5300 Rechargeable Electric Toothbrush, Black, with 3 Brush Heads
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Pink
As an affiliate, we earn on qualifying purchases.
Why Glioblastoma Remains Difficult to Treat
Glioblastoma treatment generally begins with surgery to remove as much of the tumor as possible, followed by radiation and chemotherapy to control remaining cancer and extend survival. Tumor cells can spread into surrounding brain tissue, making complete surgical removal difficult. The brain’s protective barrier also blocks many substances, including some medicines that might otherwise be considered for treatment.
MicroRNAs are small pieces of genetic material that can affect the activity of multiple genes. The UVA team is investigating whether that capacity can be used to interfere with several processes that support tumor growth, while ultrasound-assisted delivery addresses the challenge of getting the molecules into the brain. The report places the work within UVA’s wider focused-ultrasound research, including its partnership with the Focused Ultrasound Foundation on the FUSION Center, which studies focused ultrasound alongside cancer immunotherapy.
Human Safety and Benefit Unproven
The available report describes preclinical findings and does not report human testing. It does not specify the study’s sample sizes, treatment dose, duration of effect, detailed safety findings or numerical survival results. Those details are needed to judge the strength and limits of the reported animal outcomes.
It is also unclear whether the delivery method can be used safely and consistently in people, how the microRNAs might affect healthy brain tissue, or whether tumors could respond differently over time. Abounader’s stated hope for future trials is not a trial announcement. No clinical-trial start date, regulatory decision or patient eligibility information is provided.
Further Studies Before Patient Trials
The immediate next step is additional research to test the delivery approach, its safety and its effects before it can be considered for human studies. The team has said it hopes to translate the findings into future clinical trials, but the supplied report gives no timetable or confirmation that such a trial is planned or authorized.
For now, the results should be understood as an early signal from laboratory and animal research. Any future trial would need to establish whether the treatment can be delivered safely and whether the reported effects translate to patients. Until then, the findings do not alter standard glioblastoma treatment.
Key Questions
Has the ultrasound treatment been tested in people?
No human testing is reported. The work described involved laboratory experiments and animal models.
What did the treatment do in the animal studies?
The report says microRNA treatment delivered with focused ultrasound slowed tumor growth and helped animals survive longer. It provides no numerical effect sizes or follow-up details.
How is the treatment intended to get into the brain?
Researchers combined microRNA-carrying nanoparticles with microbubbles and MRI-guided focused ultrasound. The ultrasound and bubbles temporarily open the blood-brain barrier in the targeted area, according to the report.
When could clinical trials begin?
No start date is given. The team says it hopes to pursue future trials, but further research is needed, and the report does not confirm that a human trial has been scheduled.
Source: sciencedaily.com
